AIM Key Statistics, Chart & Performance
The current stock price of AIM is 1.15 USD. In the past month the price increased by 1.87%. In the past year, price increased by 447.91%.
AIM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AIM. When comparing the yearly performance of all stocks, AIM is one of the better performing stocks in the market, outperforming 99.12% of all stocks.
AIM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AIM. AIM may be in some trouble as it scores bad on both profitability and health.
AIM Financial Highlights
Over the last trailing twelve months AIM reported a non-GAAP Earnings per Share(EPS) of -20.24. The EPS increased by 58.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -391.52% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AIM Forecast & Estimates
5 analysts have analysed AIM and the average price target is 22.42 USD. This implies a price increase of 1849.36% is expected in the next year compared to the current price of 1.15.
For the next year, analysts expect an EPS growth of 77.3% and a revenue growth -51.38% for AIM
AIM Ownership
About AIM
Company Profile
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Company Info
AIM IMMUNOTECH INC
2117 Sw Highway 484
Ocala FLORIDA 34473 US
CEO: Thomas K. Equels
Employees: 21
Phone: 13524487797
AIM IMMUNOTECH INC / AIM FAQ
What does AIM IMMUNOTECH INC do?
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
What is the current price of AIM stock?
The current stock price of AIM is 1.15 USD.
What is the dividend status of AIM IMMUNOTECH INC?
AIM does not pay a dividend.
What is the ChartMill rating of AIM IMMUNOTECH INC stock?
AIM has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for AIM IMMUNOTECH INC?
AIM IMMUNOTECH INC (AIM) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for AIM stock?
AIM IMMUNOTECH INC (AIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.24).